Non-typeable Haemophilus influenzae–Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial

Posted on by

Lancet Respiratory Medicine
May 2022 Volume 10 Number 5 p421-524, e44-e50
https://www.thelancet.com/journals/lanres/issue/current

 

Articles
Non-typeable Haemophilus influenzae–Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial
Stefan Andreas,et al. on behalf of the NTHi-Mcat-002 study group